Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Apr 24, 2023
-
Dec 7, 2021- 100% Disease Control Rate (DCR): 16 of 16 evaluable patients demonstrate tumor shrinkage
-
Nov 15, 2021- Strong balance sheet of ~$386 million cash, cash equivalents and marketable securities is anticipated to fund planned operations into 2025
-
Oct 18, 2021- Former Chief Scientific Officer and Head of Tumor Biology at Pfizer will lead IDEAYA's research organization as Chief Scientific Officer
-
Aug 10, 2021- Strong balance sheet of ~$400 million cash, cash equivalents and marketable securities is anticipated to fund planned operations into 2025
-
Jun 28, 2021‒ Observed plasma SAM reduction in each of the first two dose escalation cohorts of the IDE397 Phase 1 clinical trial, satisfying the clinical protocol threshold of approximately 60% or greater plasma S-adenosyl methionine (SAM) pharmacodynamic (PD) reduction to initiate IDE397 tumor biopsy cohort for evaluation of tumor PD markers
-
May 10, 2021- Completed enrollment of initial dose escalation cohort of the Phase 1 clinical trial evaluating IDE397, a potential best-in-class MAT2A inhibitor for MTAP-deletion patients
-
May 10, 2021- Observed early clinical efficacy in first cohort of darovasertib plus crizotinib combination with tumor reduction in 2 of 2 evaluable MUM patients, including a partial response in a 3L patient with a 54% tumor reduction who is awaiting a confirmatory scan
-
Apr 16, 2021- Darovasertib monotherapy results in 57% 1-year Overall Survival (OS) Rate in predominantly 2L / 3L and heavily pre-treated (out to 7L / 8L) MUM patients, where historical 1-year OS Rate has been reported at 37%
-
Apr 15, 2021- IDE397 demonstrates significant single-agent anti-tumor activity in a 40-plus MTAP-deletion PDX study, including tumor regressions, across major solid tumor types, such as NSCLC, gastric, esophageal, and bladder cancers (AACR 2021)
-
Mar 23, 2021- Initiated Phase 1 clinical trial for IDE397, a potential best-in-class MAT2A inhibitor for patients having tumors with MTAP-deletion
-
Mar 23, 2021- Targeting enrollment of approximately 40 patients in the IDE196 and binimetinib clinical combination Phase 1/2 study in MUM
-
Feb 22, 2021‒ IDEAYA's inaugural Synthetic Lethality Investor Day is planned for April 20, 2021 with scientific presentations from IDEAYA and GSK scientific leaders, and several Key Opinion Leaders
-
Feb 17, 2021- Dr. Susan L. Kelley was a former clinical development executive in oncology with Bayer and Bristol Myers Squibb, and led the development and regulatory approval of Nexavar®
-
Feb 8, 2021‒ Targeting First-Patient-In for IDE397 Phase 1 study in Q1 2021, as a potential best-in-class MAT2A inhibitor for cancer patients harboring MTAP-deletion, which is prevalent in ~15% of all solid tumors
-
Jan 11, 2021IDE397 is being developed as a potential best-in-class MAT2A inhibitor for MTAP-deletion, which is prevalent in approximately 15% of all solid tumors
-
Nov 12, 2020- IDE397, a potential best-in-class MAT2A inhibitor for patients with solid tumors having MTAP deletion, targeting an IND-filing in December 2020
-
Oct 22, 2020- The partnership with the Sellers Laboratory at the Broad Institute of MIT and Harvard will utilize the Broad CRISPR paralog screening platform for Synthetic Lethality target and biomarker discovery, including for IDEAYA's PARG program
-
Aug 12, 2020- Established strategic partnership with GlaxoSmithKline on Synthetic Lethality programs MAT2A, Pol Theta and Werner Helicase
-
Aug 4, 2020- Closing of Glaxo Group Equity Investment of $20 Million in IDEAYA at $15.00 per share
-
Jul 16, 2020- 4 evaluable GNAQ/11 mutation skin melanoma patients enrolled in Stage 1 cohort with a 100% Disease Control Rate (excluding 1 non-evaluable) and 1 confirmed partial response by RECIST 1.1 guidelines